Pharmacotherapy for neovascular age-related macular degeneration: An analysis of the 100% 2008 medicare fee-for-service part b claims file

American Journal of Ophthalmology

Volumn 151, Issue 5, 2011, Pages 887-895.e1

  Brechner, Ross J ^a   Rosenfeld, Philip J ^b   Babish, J Daniel ^a   Caplan, Stuart ^a  

^a CENTERS FOR MEDICARE AND MEDICAID SERVICES   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; VERTEPORFIN;

ADULT; AGED; ARTICLE; DEMOGRAPHY; DRUG COST; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MEDICARE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION;

EID: 79955085045     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2010.11.017     Document Type: Article

References (54)

1. N. Congdon, B. O'Colmain, and C.C. Klaver Causes and prevalence of visual impairment among adults in the United States Arch Ophthalmol 122 4 2004 477 485 (Pubitemid 38456282)
2. D.S. Friedman, B.J. O'Colmain, and B. Munoz Prevalence of age-related macular degeneration in the United States Arch Ophthalmol 122 4 2004 564 572 (Pubitemid 38456293)
3. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trialsTAP report Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group Arch Ophthalmol 117 10 1999 1329 1345
4. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trialsTAP Report 2 TAP Study Group Arch Ophthalmol 119 2 2001 198 207
5. E.S. Gragoudas, A.P. Adamis, E.T. Cunningham Jr, M. Feinsod, and D.R. Guyer Pegaptanib for neovascular age-related macular degeneration N Engl J Med 351 27 2004 2805 2816 (Pubitemid 40051904)
6. P.J. Rosenfeld, A.A. Moshfeghi, and C.A. Puliafito Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration Ophthalmic Surg Lasers Imaging 36 4 2005 331 335 (Pubitemid 41073112)
7. R.L. Avery, D.J. Pieramici, M.D. Rabena, A.A. Castellarin, M.A. Nasir, and M.J. Giust Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration Ophthalmology 113 3 2006 363 372 e5
8. R.F. Spaide, K. Laud, and H.F. Fine Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration Retina 26 4 2006 383 390 (Pubitemid 44197628)
9. R.M. Rich, P.J. Rosenfeld, and C.A. Puliafito Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration Retina 26 5 2006 495 511 (Pubitemid 44620390)
10. P. Yoganathan, V.A. Deramo, J.C. Lai, R.K. Tibrewala, and D.M. Fastenberg Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration Retina 26 9 2006 994 998 (Pubitemid 44973217)
11. Z.F. Bashshur, A. Bazarbachi, A. Schakal, Z.A. Haddad, C.P. El Haibi, and B.N. Noureddin Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration Am J Ophthalmol 142 1 2006 1 9 (Pubitemid 43946791)
12. R.A. Costa, R. Jorge, D. Calucci, J.A. Cardillo, L.A. Melo Jr, and I.U. Scott Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study Invest Ophthalmol Vis Sci 47 10 2006 4569 4578 (Pubitemid 46579387)
13. A.E. Fung, P.J. Rosenfeld, and E. Reichel The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide Br J Ophthalmol 90 11 2006 1344 1349 (Pubitemid 44702055)
14. F.B. Aggio, M.E. Farah, W.C. Silva, and G.B. Melo Intravitreal bevacizumab for exudative age-related macular degeneration after multiple treatments Graefes Arch Clin Exp Ophthalmol 245 2 2007 215 220 (Pubitemid 46291451)
15. C.Y. Chen, T.Y. Wong, and W.J. Heriot Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: a short-term study Am J Ophthalmol 143 3 2007 510 512
16. E. Chen, R.S. Kaiser, and J.F. Vander Intravitreal bevacizumab for refractory pigment epithelial detachment with occult choroidal neovascularization in age-related macular degeneration Retina 27 4 2007 445 450 (Pubitemid 46624284)
17. M.J. Goff, R.N. Johnson, H.R. McDonald, E. Ai, J.M. Jumper, and A. Fu Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration Retina 27 4 2007 432 438 (Pubitemid 46624282)
18. J.B. Jonas, T. Libondi, and A.K. Ihloff Visual acuity change after intravitreal bevacizumab for exudative age-related macular degeneration in relation to subfoveal membrane type Acta Ophthalmol Scand 85 5 2007 563 565 (Pubitemid 47163119)
19. K.C. Madhusudhana, S.R. Hannan, and C.P. Williams Intravitreal bevacizumab (Avastin) for the treatment of choroidal neovascularization in age-related macular degeneration: results from 118 cases Br J Ophthalmol 91 12 2007 1716 1717 (Pubitemid 350207411)
20. M.V. Emerson, A.K. Lauer, and C.J. Flaxel Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration Retina 27 4 2007 439 444 (Pubitemid 46624283)
21. R. Pedersen, W. Soliman, H. Lund-Andersen, and M. Larsen Treatment of choroidal neovascularization using intravitreal bevacizumab Acta Ophthalmol Scand 85 5 2007 526 533 (Pubitemid 47163114)
22. S. Aisenbrey, F. Ziemssen, and M. Volker Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration Graefes Arch Clin Exp Ophthalmol 245 7 2007 941 948 (Pubitemid 46979534)
23. F. Giansanti, G. Virgili, and A. Bini Intravitreal bevacizumab therapy for choroidal neovascularization secondary to age-related macular degeneration: 6-month results of an open-label uncontrolled clinical study Eur J Ophthalmol 17 2 2007 230 237 (Pubitemid 46918110)
24. R. Lazic, and N. Gabric Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration Graefes Arch Clin Exp Ophthalmol 245 1 2007 68 73 (Pubitemid 46766732)
25. C.A. Cleary, S. Jungkim, K. Ravikumar, C. Kelliher, R.W. Acheson, and M. Hickey-Dwyer Intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration, 6- and 9-month results Eye (Lond) 22 1 2008 82 86
26. N.G. Ghazi, R.M. Knape, T.Q. Kirk, J.S. Tiedeman, and B.P. Conway Intravitreal bevacizumab (avastin) treatment of retinal angiomatous proliferation Retina 28 5 2008 689 695 (Pubitemid 351655120)
27. A. Melamud, S. Stinnett, and S. Fekrat Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections Am J Ophthalmol 146 1 2008 91 95
28. L. Wu, M.A. Martinez-Castellanos, and H. Quiroz-Mercado Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES) Graefes Arch Clin Exp Ophthalmol 246 1 2008 81 87 (Pubitemid 350167096)
29. P.V. Algvere, B. Steen, S. Seregard, and A. Kvanta A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations Acta Ophthalmol 86 5 2008 482 489
30. R.V. Azad, M.A. Khan, B. Chanana, and S. Azad Intravitreal bevacizumab for subfoveal choroidal neovascularization secondary to age-related macular degeneration in an Indian population Jpn J Ophthalmol 52 1 2008 52 56 (Pubitemid 351462226)
31. Z.F. Bashshur, Z.A. Haddad, A. Schakal, R.F. Jaafar, M. Saab, and B.N. Noureddin Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study Am J Ophthalmol 145 2 2008 249 256
32. G. Weigert, S. Michels, and S. Sacu Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study Br J Ophthalmol 92 3 2008 356 360 (Pubitemid 351363530)
33. K.E. Stepien, P.J. Rosenfeld, and C.A. Puliafito Comparison of intravitreal bevacizumab followed by ranibizumab for the treatment of neovascular age-related macular degeneration Retina 29 8 2009 1067 1073
34. Z.F. Bashshur, Z.A. Haddad, A.R. Schakal, R.F. Jaafar, A. Saad, and B.N. Noureddin Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: the second year of a prospective study Am J Ophthalmol 148 1 2009 59 65
35. P.J. Mekjavic, A. Kraut, M. Urbancic, E. Lenassi, and M. Hawlina Efficacy of 12-month treatment of neovascular age-related macular degeneration with intravitreal bevacizumab based on individually determined injection strategies after three consecutive monthly injections Acta Ophthalmol 2009 Forthcoming
36. C. Furino, F. Boscia, and N. Recchimurzo Intravitreal bevacizumab for treatment-naive subfoveal occult choroidal neovascularization in age-related macular degeneration Acta Ophthalmol 87 4 2009 404 407
37. J. Levy, M. Shneck, and S. Rosen Intravitreal bevacizumab (avastin) for subfoveal neovascular age-related macular degeneration Int Ophthalmol 29 5 2009 349 357
38. J.S. Schouten, E.C. La Heij, C.A. Webers, I.J. Lundqvist, and F. Hendrikse A systematic review on the effect of bevacizumab in exudative age-related macular degeneration Graefes Arch Clin Exp Ophthalmol 247 1 2009 1 11
39. D.S. Fong, P. Custis, J. Howes, and J.W. Hsu Intravitreal bevacizumab and ranibizumab for age-related macular degeneration: a multicenter, retrospective study Ophthalmology 117 2 2010 298 302
40. S. Jyothi, H. Chowdhury, M. Elagouz, and S. Sivaprasad Intravitreal bevacizumab (Avastin) for age-related macular degeneration: a critical analysis of literature Eye (Lond) 24 5 2010 816 824
41. P.J. Rosenfeld, D.M. Brown, and J.S. Heier Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 14 2006 1419 1431 (Pubitemid 44511557)
42. D.M. Brown, P.K. Kaiser, and M. Michels Ranibizumab versus verteporfin for neovascular age-related macular degeneration N Engl J Med 355 14 2006 1432 1444 (Pubitemid 44511558)
43. P. Bhatnagar, R.F. Spaide, and B.S. Takahashi Ranibizumab for treatment of choroidal neovascularization secondary to age-related macular degeneration Retina 27 7 2007 846 850 (Pubitemid 47479378)
44. N.M. Bressler Antiangiogenic approaches to age-related macular degeneration today Ophthalmology 116 10 Suppl 2009 S15 S23
45. F. Ziemssen, S. Grisanti, K.U. Bartz-Schmidt, and M.S. Spitzer Off-label use of bevacizumab for the treatment of age-related macular degeneration: what is the evidence? Drugs Aging 26 4 2009 295 320
46. M.L. Subramanian, G. Abedi, and S. Ness Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial Eye (Lond) 24 11 2010 1708 1715
47. J.C. Javitt, Z. Zhou, M.G. Maguire, S.L. Fine, and R.J. Willke Incidence of exudative age-related macular degeneration among elderly Americans Ophthalmology 110 8 2003 1534 1539 (Pubitemid 36962485)
48. E. Anastasopoulos, F. Yu, and A.L. Coleman Age-related macular degeneration is associated with an increased risk of hip fractures in the Medicare database Am J Ophthalmol 142 6 2006 1081 1083 (Pubitemid 44853884)
49. S.L. Alexander, W.T. Linde-Zwirble, and W. Werther Annual rates of arterial thromboembolic events in medicare neovascular age-related macular degeneration patients Ophthalmology 114 12 2007 2174 2178 (Pubitemid 350181138)
50. G.P. Zlateva, J.C. Javitt, S.N. Shah, Z. Zhou, and J.G. Murphy Comparison of comorbid conditions between neovascular age-related macular degeneration patients and a control cohort in the medicare population Retina 27 9 2007 1292 1299 (Pubitemid 350211540)
51. Y. Duan, J. Mo, and R. Klein Age-related macular degeneration is associated with incident myocardial infarction among elderly Americans Ophthalmology 114 4 2007 732 737 (Pubitemid 46483682)
52. D. Liao, J. Mo, and Y. Duan Is age-related macular degeneration associated with stroke among elderly Americans? Open Ophthalmol J 2 2008 37 42
53. A. Wysong, P.P. Lee, and F.A. Sloan Longitudinal incidence of adverse outcomes of age-related macular degeneration Arch Ophthalmol 127 3 2009 320 327
54. A.L. Coleman, and F. Yu Eye-related medicare costs for patients with age-related macular degeneration from 1995 to 1999 Ophthalmology 115 1 2008 18 25